The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer
Open accessAbstract
Current treatments for castration-resistant prostate cancer (CRPC) that target androgen receptor (AR) signaling improve patient survival, yet ultimately fail. Here, we provide novel insights into treatment response for the antiandrogen abiraterone by analyses of a genetically engineered mouse (GEM) model with combined inactivation of Trp53 and Pten, which are frequently comutated in human CRPC. These NPp53 mice fail to respond to abiraterone and display accelerated progression to tumors resembling treatment-related CRPC with neuroendocrine differentiation (CRPC-NE) in humans. Cross-species computational analyses identify master regulators of adverse response that are conserved with human CRPC-NE, including the neural differentiation factor SOX11, which promotes neuroendocrine differentiation in cells derived from NPp53 tumors. Furthermore, abiraterone-treated NPp53 prostate tumors contain regions of focal and/or overt neuroendocrine differentiation, distinguished by their proliferative potential. Notably, lineage tracing in vivo provides definitive and quantitative evidence that focal and overt neuroendocrine regions arise by transdifferentiation of luminal adenocarcinoma cells. These findings underscore principal roles for TP53 and PTEN inactivation in abiraterone resistance and progression from adenocarcinoma to CRPC-NE by transdifferentiation. Significance: Understanding adverse treatment response and identifying patients likely to fail treatment represent fundamental clinical challenges. By integrating analyses of GEM models and human clinical data, we provide direct genetic evidence for transdifferentiation as a mechanism of drug resistance as well as for stratifying patients for treatment with antiandrogens. Cancer Discov; 7(7); 736–49. ©2017 AACR. See related commentary by Sinha and Nelson, p. 673. This article is highlighted in the In This Issue feature, p. 653
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,701
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Self-citationGenotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
The Molecular Taxonomy of Primary Prostate Cancer
Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, C. D., Annala, M., Aprikian, A., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,110
Self-citationThe mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517 · cited 3×
“Correlating with their distinct disease outcomes, genomic sequencing analyses have revealed that locally-invasive and advanced prostate cancer have profound differences in their mutational landscapes (12-18).”
BackgroundCrucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Beltran, H., Prandi, D., Mosquera, J. M., Benelli, M., Puca, L., Cyrta, J., Marotz, C., Giannopoulou, E., Chakravarthi, B. V. S. K., Varambally, S., et al. (2016) · Nature Medicine · doi:10.1038/nm.4045 · Cited by 1,685
Self-citationExome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
Barbieri, C. E., Baca, S. C., Lawrence, M. S., Demichelis, F., Blattner, M., Theurillat, J.-P., White, T. A., Stojanov, P., Van Allen, E., Stransky, N., et al. (2012) · Nature Genetics · doi:10.1038/ng.2279 · Cited by 1,558
Self-citationEmerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Watson, P. A., Arora, V. K., & Sawyers, C. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4016 · Cited by 1,536
Punctuated Evolution of Prostate Cancer Genomes
Baca, S. C., Prandi, D., Lawrence, M. S., Mosquera, J. M., Romanel, A., Drier, Y., Park, K., Kitabayashi, N., MacDonald, T. Y., Ghandi, M., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.021 · Cited by 1,320
Self-citationProstate cancer in a transgenic mouse.
Greenberg, N. M., DeMayo, F., Finegold, M. J., Medina, D., Tilley, W. D., Aspinall, J. O., Cunha, G. R., Donjacour, A. A., Matusik, R. J., & Rosen, J. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3439 · Cited by 1,294
Linking the p53 tumour suppressor pathway to somatic cell reprogramming
Kawamura, T., Suzuki, J., Wang, Y. V., Menendez, S., Morera, L. B., Raya, A., Wahl, G. M., & Belmonte, J. C. I. (2009) · Nature · doi:10.1038/nature08311 · Cited by 1,115
Ku, S. Y., Rosario, S., Wang, Y., Mu, P., Seshadri, M., Goodrich, Z. W., Goodrich, M. M., Labbé, D. P., Gomez, E. C., Wang, J., et al. (2017) · Science · doi:10.1126/science.aah4199 · Cited by 1,089
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
Self-citationMu, P., Zhang, Z., Benelli, M., Karthaus, W. R., Hoover, E., Chen, C.-C., Wongvipat, J., Ku, S.-Y., Gao, D., Cao, Z., et al. (2017) · Science · doi:10.1126/science.aah4307 · Cited by 1,050
Self-citationA p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity
Marión, R. M., Strati, K., Li, H., Murga, M., Blanco, R., Ortega, S., Fernandez-Capetillo, O., Serrano, M., & Blasco, M. A. (2009) · Nature · doi:10.1038/nature08287 · Cited by 1,028 · cited 1×
“In contrast, a general role for the p53 pathway in regulating cellular reprogramming has been previously suggested by studies showing that inhibition of p53 pathway activity results in increased efficiency in the formation of induced pluripotent stem cells (43-47).”
BackgroundScher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
Beltran, H., Rickman, D. S., Park, K., Chae, S. S., Sboner, A., MacDonald, T. Y., Wang, Y., Sheikh, K. L., Terry, S., Tagawa, S. T., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0130 · Cited by 999
Self-citationAttard, G., Parker, C., Eeles, R. A., Schröder, F., Tomlins, S. A., Tannock, I., Drake, C. G., & de Bono, J. S. (2016) · The Lancet · doi:10.1016/s0140-6736(14)61947-4 · Cited by 905
Immortalization eliminates a roadblock during cellular reprogramming into iPS cells
Utikal, J., Polo, J. M., Stadtfeld, M., Maherali, N., Kulalert, W., Walsh, R. M., Khalil, A., Rheinwald, J. G., & Hochedlinger, K. (2009) · Nature · doi:10.1038/nature08285 · Cited by 836
A luminal epithelial stem cell that is a cell of origin for prostate cancer
Wang, X., Julio, M. K.-D., Economides, K. D., Walker, D., Yu, H., Halili, M. V., Hu, Y.-P., Price, S. M., Abate-Shen, C., & Shen, M. M. (2009) · Nature · doi:10.1038/nature08361 · Cited by 734
Self-citationKretzschmar, K., & Watt, F. M. (2012) · Cell · doi:10.1016/j.cell.2012.01.002 · Cited by 714
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
Niederst, M. J., Sequist, L. V., Poirier, J. T., Mermel, C. H., Lockerman, E. L., Garcia, A. R., Katayama, R., Costa, C., Ross, K. N., Moran, T., et al. (2015) · Nature Communications · doi:10.1038/ncomms7377 · Cited by 647
Genomic hallmarks of localized, non-indolent prostate cancer
Fraser, M., Sabelnykova, V. Y., Yamaguchi, T. N., Heisler, L. E., Livingstone, J., Huang, V., Shiah, Y.-J., Yousif, F., Lin, X., Masella, A. P., et al. (2017) · Nature · doi:10.1038/nature20788 · Cited by 600
Mostaghel, E. A., Marck, B. T., Plymate, S. R., Vessella, R. L., Balk, S., Matsumoto, A. M., Nelson, P. S., & Montgomery, R. B. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0728 · Cited by 588
Self-citationN-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer
Dardenne, E., Beltran, H., Benelli, M., Gayvert, K., Berger, A., Puca, L., Cyrta, J., Sboner, A., Noorzad, Z., MacDonald, T., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.005 · Cited by 559
Self-citationBishop, J. L., Thaper, D., Vahid, S., Davies, A., Ketola, K., Kuruma, H., Jama, R., Nip, K. M., Angeles, A., Johnson, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1263 · Cited by 418
Self-citationN-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells
Lee, J. K., Phillips, J. W., Smith, B. A., Park, J. W., Stoyanova, T., McCaffrey, E. F., Baertsch, R., Sokolov, A., Meyerowitz, J. G., Mathis, C., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.001 · Cited by 407
The establishment of neuronal properties is controlled by Sox4 and Sox11
Bergsland, M., Werme, M., Malewicz, M., Perlmann, T., & Muhr, J. (2006) · Genes & Development · doi:10.1101/gad.403406 · Cited by 339
Selective Evolution of Stromal Mesenchyme with p53 Loss in Response to Epithelial Tumorigenesis
Hill, R., Song, Y., Cardiff, R. D., & Van Dyke, T. (2005) · Cell · doi:10.1016/j.cell.2005.09.030 · Cited by 324
Aytes, A., Mitrofanova, A., Lefebvre, C., Alvarez, M. J., Castillo-Martin, M., Zheng, T., Eastham, J. A., Gopalan, A., Pienta, K. J., Shen, M. M., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.017 · Cited by 324
Self-citationSynergy of p53 and Rb Deficiency in a Conditional Mouse Model for Metastatic Prostate Cancer
Zhou, Z., Flesken-Nikitin, A., Corney, D. C., Wang, W., Goodrich, D. W., Roy-Burman, P., & Nikitin, A. Y. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0486 · Cited by 316
Sequentially acting Sox transcription factors in neural lineage development
Bergsland, M., Ramsköld, D., Zaouter, C., Klum, S., Sandberg, R., & Muhr, J. (2011) · Genes & Development · doi:10.1101/gad.176008.111 · Cited by 311
Hirano, D., Okada, Y., Minei, S., Takimoto, Y., & Nemoto, N. (2004) · European Urology · doi:10.1016/j.eururo.2003.11.032 · Cited by 303
Aparicio, A. M., Shen, L., Tapia, E. L. N., Lu, J.-F., Chen, H.-C., Zhang, J., Wu, G., Wang, X., Troncoso, P., Corn, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1259 · Cited by 295
Sock, E., Rettig, S. D., Enderich, J., Bösl, M. R., Tamm, E. R., & Wegner, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.15.6635-6644.2004 · Cited by 267
Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
Li, Z., Bishop, A. C., Alyamani, M., Garcia, J. A., Dreicer, R., Bunch, D., Liu, J., Upadhyay, S. K., Auchus, R. J., & Sharifi, N. (2015) · Nature · doi:10.1038/nature14406 · Cited by 256
Ferone, G., Song, J.-Y., Sutherland, K. D., Bhaskaran, R., Monkhorst, K., Lambooij, J.-P., Proost, N., Gargiulo, G., & Berns, A. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.001 · Cited by 244
Scher, H. I., Solo, K., Valant, J., Todd, M. B., & Mehra, M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139440 · Cited by 238
The Many Faces of Neuroendocrine Differentiation in Prostate Cancer Progression
Terry, S., & Beltran, H. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00060 · Cited by 238
Masumori, N., Thomas, T. Z., Chaurand, P., Case, T. C., Paul, M., Kasper, S. F., Caprioli, R. M., Tsukamoto, T., Shappell, S. B., & Matusik, R. J. (2001) · PubMed · Cited by 228
ERG gene rearrangements are common in prostatic small cell carcinomas
Lotan, T. L., Gupta, N. S., Wang, W., Toubaji, A., Haffner, M. C., Chaux, A., Hicks, J. L., Meeker, A. K., Bieberich, C. J., De Marzo, A. M., et al. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.7 · Cited by 218
Molecular sampling of prostate cancer: a dilemma for predicting disease progression
Sboner, A., Demichelis, F., Calza, S., Pawitan, Y., Setlur, S. R., Hoshida, Y., Perner, S., Adami, H.-O., Fall, K., Mucci, L. A., et al. (2010) · BMC Medical Genomics · doi:10.1186/1755-8794-3-8 · Cited by 218
Self-citationBhattaram, P., Penzo-Méndez, A., Sock, E., Colmenares, C., Kaneko, K. J., Vassilev, A., DePamphilis, M. L., Wegner, M., & Lefebvre, V. (2010) · Nature Communications · doi:10.1038/ncomms1008 · Cited by 217
Molecular Alterations in Primary Prostate Cancer after Androgen Ablation Therapy
Best, C. J. M., Gillespie, J. W., Yi, Y., Chandramouli, G. V. R., Perlmutter, M. A., Gathright, Y., Erickson, H. S., Georgevich, L., Tangrea, M. A., Duray, P. H., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0585 · Cited by 186
Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy
Li, Z., Alyamani, M., Li, J., Rogacki, K., Abazeed, M., Upadhyay, S. K., Balk, S. P., Taplin, M.-E., Auchus, R. J., & Sharifi, N. (2016) · Nature · doi:10.1038/nature17954 · Cited by 171
Luminal Cells Are Favored as the Cell of Origin for Prostate Cancer
Wang, Z. A., Toivanen, R., Bergren, S. K., Chambon, P., & Shen, M. M. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.002 · Cited by 168
Self-citationLunardi, A., Ala, U., Epping, M. T., Salmena, L., Clohessy, J. G., Webster, K. A., Wang, G., Roberta Mazzucchelli, A., Bianconi, M., Stack, E. C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2650 · Cited by 152
Hubbard, G. K., Mutton, L. N., Khalili, M., McMullin, R. P., Hicks, J. L., Bianchi-Frias, D., Horn, L. A., Kulaç, İ., Moubarek, M. S., Nelson, P. S., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3280 · Cited by 136
Rasmussen, M. A., Holst, B., Tümer, Z., Johnsen, M. G., Zhou, S., Stummann, T. C., Hyttel, P., & Clausen, C. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.07.006 · Cited by 135
Berruti, A., Mosca, A., Porpiglia, F., Bollito, E., Tucci, M., Vana, F., Cracco, C. M., TORTA, M., Russo, L. M., Cappia, S., et al. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.05.018 · Cited by 101
Akdemir, K. C., Jain, A. K., Allton, K. L., Aronow, B. J., Xu, X., Cooney, A. J., Li, W., & Barton, M. C. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt866 · Cited by 95
Floc’h, N., Kinkade, C. W., Kobayashi, T., Aytés, À., Lefèbvre, C., Mitrofanova, A., Cardiff, R. D., Califano, A., Shen, M. M., & Abate-Shen, C. T. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0283 · Cited by 91
Self-citationMultiple Roles of p53-Related Pathways in Somatic Cell Reprogramming and Stem Cell Differentiation
Yi, L., Lu, C.-W., Hu, W., Sun, Y., & Levine, A. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1451 · Cited by 87
Self-citationBasal Progenitors Contribute to Repair of the Prostate Epithelium Following Induced Luminal Anoikis
Toivanen, R., Mohan, A., & Shen, M. M. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.03.007 · Cited by 67
Self-citationPredicting Drug Response in Human Prostate Cancer from Preclinical Analysis of In Vivo Mouse Models
Mitrofanova, A., Aytés, À., Zou, M., Shen, M. M., Abate-Shen, C. T., & Califano, A. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.051 · Cited by 41
Self-citationCouto, S. S., Cao, M., Duarte, P. C. X., Banach-Petrosky, W. A., Wang, S., Romanienko, P. J., Wu, H., Cardiff, R. D., Abate-Shen, C. T., & Cunha, G. R. (2009) · Differentiation · doi:10.1016/j.diff.2008.09.010 · Cited by 39
Self-citationKela, I., Harmelin, A., Waks, T., Orr‐Urtreger, A., Domany, E., & Eshhar, Z. (2009) · The Prostate · doi:10.1002/pros.20950 · Cited by 15
Cited by
Rebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., Van der Kwast, T., & Bristow, R. G. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00243-0 · Cited by 1,090
The great escape: tumour cell plasticity in resistance to targeted therapy
Boumahdi, S., & de Sauvage, F. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0044-1 · Cited by 761
Genetics and biology of prostate cancer
Wang, G., Zhao, D., Spring, D. J., & DePinho, R. A. (2018) · Genes & Development · doi:10.1101/gad.315739.118 · Cited by 750
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling
Bluemn, E. G., Coleman, I. M., Lucas, J. M., Coleman, R. T., Hernandez-Lopez, S., Tharakan, R., Bianchi-Frias, D., Dumpit, R. F., Kaipainen, A., Corella, A. N., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.003 · Cited by 744
“While AR repression can allow for cellular reprogramming and transdifferentiation to NE carcinoma (Ku et al., 2017; Zou et al., 2017), our results indicate that the acquisition of NE characteristics may represent a continuum of differentiation from ARPC to DNPC to NEPC, although the acquisition of…”
BackgroundSelf-citationLineage plasticity in cancer: a shared pathway of therapeutic resistance
Quintanal-Villalonga, Á., Chan, J. M., Yu, H. A., Pe’er, D., Sawyers, C. L., Sen, T., & Rudin, C. M. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0340-z · Cited by 572
Metadata
- Authors
- Zou, M., Toivanen, R., Mitrofanova, A., Floch, N., Hayati, S., Sun, Y., Le Magnen, C., Chester, D., Mostaghel, E. A., Califano, A., Rubin, M. A., Shen, M. M., & Abate-Shen, C.
- Venue
- Cancer Discovery
- Published
- 2017-07-01
- Volume
- 7
- Issue
- 7
- Pages
- 736-749
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2607041430
- Cited by
- 386
- References
- 58
- FWCI
- 28.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.